Our strategy is to focus on women to try to prevent cervical cancer in the most cost effective way. We intend to seek licensure for a broad age range.

For our cervical cancer vaccine we pursued the objective of inducing a strong immune response and protection that lasts. We are encouraged by a sustained enhanced antibody response we saw with an HPV vaccine formulated with our novel adjuvant.

The concentrations of antibodies to the virus were twice as high in the bloodstreams of the young girls.

We're pretty close and we hope to announce a filing date soon.

But now we have firm data showing we should use (it) in most women with advanced ovarian cancer who have had successful surgery to remove the bulk of their tumor.

This may tip the scales for some of those women. We could have significantly fewer cases of breast cancer in this country.